Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 6/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.49 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14813333 | 1.00 | CNR1 (0.49) | CNR1ALDH1A1CNR2MEN1KMT2A | |
| SCHEMBL28044706 | 0.88 | ALDH1A1 (0.46) | CNR1ALDH1A1CNR2KMT2AMAPT | |
| SCHEMBL11296642 | 0.84 | ALDH1A1 (0.45) | CNR1ALDH1A1CNR2MAPT | |
| SCHEMBL14813331 | 0.83 | ALDH1A1 (0.37) | CNR1ALDH1A1CNR2KMT2AMAPT | |
| SCHEMBL14813332 | 0.83 | ALDH1A1 (0.37) | CNR1ALDH1A1CNR2KMT2AMAPT | |
| SCHEMBL11306763 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CNR2MEN1KMT2AMAPT | |
| SCHEMBL679131 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CNR2MEN1KMT2AMAPT | |
| SCHEMBL679130 | 0.81 | ALDH1A1 (0.46) | ALDH1A1CNR2MEN1KMT2AMAPT | |
| SCHEMBL9111857 | 0.81 | ZDHHC20 (0.50) | CNR1ALDH1A1CNR2MAPTHPGD | |
| SCHEMBL19261723 | 0.81 | ZDHHC20 (0.50) | CNR1ALDH1A1CNR2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | Shanghai Pharmaceuticals Holding Cd., Ltd. (CN) | 2023-02-14 | — | — | US | disclosed |
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190091-A1 | NITROGENOUS HETEROCYCLIC COMPOUND, PREPARATION METHOD, INTERMEDIATE, COMPOSITION, AND APPLICATION | ERBB2, EGFR, ERBB4 | CNR1 1158/4885ALDH1A1 3963/4885CNR2 1015/4885 |
| US-11578074-B2 | Nitrogenous heterocyclic compound, preparation method, intermediate, composition, and application | ERBB2, EGFR, ERBB4 | CNR1 1167/4885ALDH1A1 4057/4885CNR2 980/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.